510(k)-Exempt Devices and Their Remaining Regulatory Duties

1. Key takeaways

A device exempted from 510(k) must still fulfill four obligations: establishment registration, device listing, QMSR quality system requirements, and medical device reporting (MDR). In addition, it must satisfy labeling (21 CFR 801) and UDI (21 CFR 830) requirements. Exemption from 510(k) removes only the premarket notification track, not the full set of market obligations. Companies that read exemption as a broad release from oversight underestimate the work that remains, and they usually discover the gap during an inspection or at customs, when the missing records are hardest to assemble. The correct mental model is that exemption simplifies one pathway while leaving every other duty intact, and the compliance program should be built and resourced accordingly from the first day of the project. Budgeting, staffing, and audit schedules should all assume the full duty set, with exemption treated purely as a premarket matter.

• Exemption status is expressed as a product code plus conditions, not as an unconditional release.
• Conditions attached to exemptions typically limit intended use, sterility, or technical features; exceeding them forfeits the exemption and triggers a 510(k).
• Under 21 CFR 807.28(f), exempt devices under one product code share a single listing number.
• After the QMSR takes effect on 2026-02-02, quality system duties rest on the clauses of ISO 13485:2016 as incorporated into 21 CFR Part 820.
• MDR event files and annual review mechanisms apply to exempt devices just as they do to cleared ones.

2. Legal basis

The authorities below define the exemption mechanism and the duties that survive it. The exemption statements in the classification regulations are conditional by nature, and the precise wording for a given product code controls what the manufacturer may and may not do while claiming the benefit of exemption.

3. Expert insights

Insight one: exemption status is expressed as a product code plus conditions, not as an unconditional waiver.

The exemption statements in 21 CFR 862 through 892 ordinarily carry limiting conditions, for example restricting the intended use to particular indications, restricting the sterility status, or excluding devices that incorporate particular technical features. Stepping outside the stated scope forfeits the exemption, and a 510(k) must then be submitted. This structure means that a claim of exemption is never a single fact but a set of facts that must all continue to hold as the product evolves. Design changes, new indications, new packaging configurations, or new manufacturing sites can each quietly push a product outside the exemption conditions, so the exemption file needs to be revisited whenever any of those events occurs rather than being archived after the first determination.

Insight two: exempt devices are listed through the exempt product code channel and share one listing number.

Under 21 CFR 807.28(f), FDA assigns a single listing number to all devices under the same exempt product code; for non-exempt devices, one listing number is assigned for each FDA premarket submission number. This directly determines the structure of the listing ledger. A company with a broad exempt catalog should organize its records by product code, confirming that every catalog item genuinely falls within the exempt scope of the code under which it is grouped, because a mis-grouped device inherits an exemption it does not actually hold. The grouping logic also drives how new models are added, so the ledger design should be settled before the first listing submission is made rather than reworked afterwards.

Insight three: once the QMSR takes effect on 2026-02-02, the quality system obligations for exempt devices rest on the clauses of ISO 13485:2016.

Following the amendment of 21 CFR Part 820, the rule incorporates ISO 13485:2016 by reference. Even where a product is exempt from 510(k), the manufacturing establishment must still establish and maintain a quality system under the QMSR, and FDA may conduct inspections under the compliance program 7382.850. The consequence for planning is that exempt status brings no relief on the quality system side: documentation, process validation, supplier controls, and complaint handling must all exist at the same depth as for cleared devices, and inspection readiness is judged against the same standard when FDA arrives at the site. Treating the QMSR program and the exemption analysis as one integrated work stream, rather than two separate tracks owned by different teams, keeps the two documents consistent over time.

4. Practical recommendations

• Verify the exemption conditions for the product code in 21 CFR 862 through 892 word for word, and write those conditions into the product release checklist so that every release decision checks against them.
• Group listings under the exempt product code as the regulation directs, avoiding duplicate listing-number applications for multiple specifications under the same code.
• Establish an MDR event file and an annual review mechanism for exempt products as well, since reporting duties do not track exemption status.
• Plan UDI assignment and GUDID data submission alongside everything else, because these duties are not waived by 510(k) exemption.

5. Verification checklist

• □ The 510(k) exemption conditions for the product code have been recorded word for word.
• □ It has been confirmed that the product does not touch any limitation that would forfeit the exemption.
• □ Listing has been completed under the exempt product code, with the correct listing number structure.
• □ QMSR system documentation has been established and the DMR and DHR are retained.
• □ UDI assignment and GUDID data submission have been completed.

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com